Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203034 · ClinicalTrials.gov registry record · Phase 3
Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 472
- Enrollment target
NCT00203034 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 472 participants.
The verdict
NCT00203034, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 472 participants
- Enrollment target
Study Summary
Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo
Interventions
- OTHER Placebo
- DRUG rasagiline mesylate
- DRUG 1.0 mg rasagiline mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 472 participants |
| Start Date | 2000-05 |
| Est. Completion | 2003-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00203034
The ClinicalTrials.gov registry entry for NCT00203034 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 472 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00203034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00203034 about?
NCT00203034 is a clinical study titled "Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations". Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo
What is the current status of trial NCT00203034?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 472 participants. The study started on 2000-05. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00203034?
The interventions under investigation include: Placebo (OTHER), rasagiline mesylate (DRUG), 1.0 mg rasagiline mesylate (DRUG).
Who is sponsoring clinical trial NCT00203034?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.